Taysha Gene Therapies (TSHA)

• Market cap: $1.84B
• 1 day: 1.91%
• 5 days: -0.47%
• 1 month: 57%
• 3 months: 41.69%
• 6 months: 30.14%
• Year to date: 21.71%
• 1 year: 229.38%
• 5 years: -75.24%
• 10 years: -73.44%
• Sector: Healthcare
• Industry: Biotechnology

About: Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Employees: 99